Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

4(50.0%)

8Total

Phase 1(4)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07472361Phase 1Completed

A Study of ENX-104 in Healthy Participants

Role: lead

NCT07253246Phase 1Recruiting

ENX-205 SAD/PET Study in Healthy Adults

Role: lead

NCT07193563Phase 2Completed

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

Role: lead

NCT07253324Phase 1Completed

ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

Role: lead

NCT07253272Phase 1Completed

A PET Study of ENX-104 in Healthy Volunteers

Role: lead

NCT05749055Phase 2Completed

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Role: lead

NCT06653296Phase 2Completed

A Dose-Response Safety Study of ENX-102 in Patients With GAD

Role: lead

NCT05481905Phase 2Withdrawn

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

Role: lead

All 8 trials loaded